# Tavotek

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tavotek

- Industry: Biotechnology
- Headquarters: US
- Website: www.tavotek.com
- Total disclosed funding: $51M
- Latest round: Series B (Nov 18, 2021)
- Investors on record: 11

## About

Founded in 2019 and based in Suzhou, China. Tavotek is an innovative large-molecule biopharmaceutical developer who focuses on the development of therapeutic medicines for patients. The company's Chief Operations Officer Mr. Wei Zhang was the head of Digital Health and Information Technology at the Johnson and Johnson (J&J) before joining in the company.

The company has 3 R&D platform for biologics include Phage Display Library, Engineering platform for tissue-specific biologics, and Multicyclic peptide platform. Along with these platforms, it has a pipeline of product candidates focused on cancers, autoimmune conditions, and infectious diseases in various stages of development.

## Funding rounds

- Series B, Nov 18, 2021, $31M — CS Capital, EnfraGen, FC Capital - China
- Series A, Mar 28, 2021, $20M — Oriza Holdings, New Alliance Capital, GF Xinde Investment, YuanBio Venture, Tsing Song Capital, Ming Bioventures, Lanhu Capital
- Series A, Mar 19, 2021 — GF Xinde Investment, Tsing Song Capital, Lanhu Capital
- Series A, Dec 4, 2020 — Oriza Holdings, New Alliance Capital, YuanBio Venture, Ming Bioventures
- Series A, May 1, 2019 — Apricot Capital

## Investors

- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Series A
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A
- New Alliance Capital (https://capitalatlas.ai/funds/new-alliance-capital) — Series A
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- Ming Bioventures (https://capitalatlas.ai/funds/ming-bioventures) — Series A
- GF Xinde Investment (https://capitalatlas.ai/funds/gf-xinde-investment) — Series A
- Tsing Song Capital (https://capitalatlas.ai/funds/tsing-song-capital) — Series A
- Lanhu Capital (https://capitalatlas.ai/funds/lanhu-capital) — Series A
- CS Capital — Series B
- EnfraGen — Series B
- FC Capital - China (https://capitalatlas.ai/funds/fc-capital-china) — Series B